Vitamin C Intake and Kidney Stone Risk in Women:
What Did a Large Prospective Study Show?
Vitamin C can be metabolised in the body to form oxalate, and urinary oxalate is an important contributor to the formation of calcium oxalate kidney stones.
This raises a practical clinical question: does higher vitamin C intake increase kidney stone risk? This large prospective study followed women over many years and provides population-level risk information that differs substantially from individual case reports.
What Did the Study Do?
The researchers prospectively followed women with no previous history of kidney stones and used dietary questionnaires to estimate vitamin C intake from both food and supplements.
What Did the Study Observe?
In this large cohort of women, higher vitamin C intake was not associated with a clear increase in the risk of symptomatic kidney stones.
95% CI: 0.69–1.64
What Question Does This Study Help Answer?
Unlike earlier case reports of oxalate nephropathy, this large cohort study provides long-term risk information from a general female population.
Cohort Study
Kidney Stone Risk in a General Female Population
The study followed a large number of women without previous kidney stones and examined the relationship between habitual dietary and supplemental vitamin C intake and subsequent symptomatic kidney stone formation.
Case Reports
Oxalate Nephropathy Signals in Specific Clinical Situations
Earlier case reports mainly described individual patients who developed calcium oxalate crystal deposition and kidney injury after very high ascorbate exposure or in the presence of relevant renal risk factors.
How Should This Study Be Interpreted?
Strength
Large Sample and Long Follow-Up
The inclusion of 85,557 women and 14 years of follow-up provides far more useful information about population-level risk than a single case report.
Finding
No Clear Increase in Risk Was Seen in Women
Even in the highest intake category of 1,500 mg per day or more, the study did not observe a statistically significant increase in symptomatic kidney stone risk.
Limitation
The Findings Cannot Be Directly Applied to High-Dose Intravenous Use
The study assessed vitamin C intake from food and oral supplements, not high-dose intravenous ascorbate.
Why Can an Oral Intake Study Not Directly Represent High-Dose Intravenous Vitamin C?
The route of vitamin C administration has a major effect on plasma concentrations and overall exposure. Oral intake and high-dose intravenous administration therefore need to be interpreted separately.
“No Clear Risk Increase with Oral Intake” Does Not Mean “No Renal Risk with High-Dose Intravenous Use”
Pharmacokinetic research shows that intravenous vitamin C can produce substantially higher plasma concentrations than the same dose given orally, with the difference becoming larger as dose increases. Evidence from different administration routes therefore should not be treated as interchangeable.
Dietary Intake and Oral Supplements
Oral vitamin C is limited by mechanisms such as intestinal absorption, tissue uptake and renal regulation, resulting in relatively strict control of plasma concentrations.
High-Dose Intravenous Vitamin C
Intravenous administration bypasses the limitations of intestinal absorption and can produce plasma concentrations far higher than those achieved with oral intake. Therefore, the degree of exposure and the context for safety assessment are not the same.
Which Factors Still Need to Be Assessed for High-Dose Intravenous Vitamin C?
A large oral-intake study does not replace the individual safety assessment required before high-dose intravenous vitamin C is considered.
How Does BMS Clinic View This Evidence?
When evaluating vitamin C and renal safety, general oral intake and high-dose intravenous administration need to be distinguished. Not all studies involving “vitamin C” should be interpreted within the same risk framework.
This large female cohort study found that, among women without a previous history of kidney stones, higher vitamin C intake from diet and oral supplements was not clearly associated with an increased risk of symptomatic kidney stones.
High-dose intravenous vitamin C, however, produces a substantially different pattern of plasma exposure from oral intake. BMS Clinic therefore emphasises professional assessment based on the actual route of administration, dose, renal function, kidney history, and other individual health factors.
This article is provided for medical education and literature reference only. It does not replace diagnosis, assessment, or personalized medical advice from a qualified healthcare professional.
The study described is a large prospective observational study. Among the women included in the study who had no prior history of kidney stones, higher oral vitamin C intake was not associated with a clear increase in the risk of symptomatic kidney stones. However, an observational study cannot completely exclude the influence of other factors or establish that all intake levels or all populations are free from related risks.
This study primarily evaluated vitamin C obtained through diet and oral supplements, and its findings should not be directly applied to high-dose intravenous vitamin C. Different routes of administration, doses, and individual kidney health require separate assessment. Before considering high-dose intravenous vitamin C, patients should undergo individualized evaluation by a qualified healthcare professional based on kidney function, history of kidney stones or kidney disease, and other relevant risk factors.
Learn More About Vitamin C and Kidney Safety Assessment
This large prospective study in women found that higher oral vitamin C intake was not clearly associated with an increased risk of symptomatic kidney stones. However, these findings should not be directly applied to high-dose intravenous vitamin C. When intravenous use is being considered, kidney function, a history of kidney stones or kidney disease, hydration status, and other factors that may affect oxalate formation or excretion should still be professionally assessed.